Real-World Cost-Effectiveness of Palliative Care for Terminal Cancer Patients in a Japanese General Hospital

• Published in: Journal of palliative medicine
• Main Authors: Hashimoto, Yuki, Hayashi, Akitoshi, Teng, Lida, Igarashi, Ataru
• Format: Journal Article
• Language: English
• Published: United States 01.09.2021
• Subjects: QALY; cost-effectiveness; end of life; palliative care; terminal cancer
• ISSN: 1557-7740
• DOI: 10.1089/jpm.2020.0649

The concept of cost-effectiveness is necessary for optimal utilization of limited health care resources. However, few studies have assessed the cost-effectiveness of palliative care using quality-adjusted life years (QALYs), considered common outcomes in health economics. We aimed to perform a cost-effectiveness analysis of palliative care for terminal cancer patients by using QALYs. A retrospective cohort study was performed. We included 401 patients with stage IV cancer, who were hospitalized and died at a Japanese general hospital during the period April 2014 to March 2019. Using the hospital database, we compared the total admission costs and QALYs based on pain levels of patients admitted to the palliative care (PC) department with those of patients admitted to other usual care (UC) departments. Patients in each group were matched through propensity scores to reduce bias. Bootstrapping estimated the 95% confidence intervals (95% CIs) and the probability that PC was more cost-effective than UC. After matching, 128 patients in each group were selected. Converting 1 U.S. dollar (USD) to 100 Japanese yen, PC reduced mean total admission costs by 1732 USD (95% CI: 1584-1879) and improved mean health benefits by 0.0028 QALYs (95% CI: 0.0025-0.0032) compared with UC. Based on the Japanese cost-effectiveness threshold, there was an 82% probability that PC was more cost-effective than UC. Our results indicated that admission of terminal cancer patients to the PC department was associated with improvement in cost-effectiveness. This finding could support the introduction of palliative care for terminal cancer patients. Our study was approved at St. Luke's International University (receipt number 18-R061 and at the Graduate School of Pharmaceutical Sciences, The Univesity of Tokyo (receipt number 31-29).